A Chinese brain-implant company’s IPO prospectus was accepted by the Shanghai Stock Exchange on 11 June 2026. Neuracle Technology (Shanghai) Co., Ltd., Chinese name 博睿康 (Boruikang), holds the world’s first commercial invasive brain-computer interface clearance, granted by China’s National Medical Products Administration on 13 March 2026 for its NEO implant in spinal cord injury. The same company has now filed for a listing on the STAR Market sci-tech innovation board with CITIC Securities as sponsor, targeting RMB 2.5 billion (approximately $345 million at current rates) in IPO proceeds. The acceptance is the first regulatory milestone of multiple in STAR Market’s review process. Listing committee approval, China Securities Regulatory Commission registration, pricing, and first day of trading are still ahead. A separate Chinese BCI maker, BrainCo, filed a confidential Hong Kong Stock Exchange prospectus five months earlier, in January 2026. Whoever clears its review first becomes the first publicly listed pure-play BCI company in the world.

What Neuracle is and what NEO does

Neuracle was founded in 2011 by Tsinghua University biomedical engineering doctorates Xu Honglai and Huang Xiaoshan. The company was previously headquartered in Changzhou and re-registered in Shanghai in 2025 in preparation for the IPO process. Its flagship product is the NEO, an epidural brain-computer interface implant with eight electrodes that sits above the dura mater without penetrating cortical tissue. The NEO received National Medical Products Administration approval on 13 March 2026 for spinal cord injury, the first commercial invasive BCI clearance in the world.

Epidural placement gives the NEO a less invasive surgical profile than the intracortical implants Neuralink and Paradromics are scaling, at the cost of lower channel count and lower decoder bandwidth. A safer surgical procedure widens the addressable spinal cord injury population and gives the device a viable first-line indication before higher-bandwidth interfaces complete regulatory review.

What the prospectus discloses

The prospectus filed with the Shanghai Stock Exchange names CITIC Securities as sponsor and routes the listing through STAR Market’s fifth listing standard (科创板第五套标准), the pre-profit track that requires the company to demonstrate profitability within four years of listing. Use of the RMB 2.5 billion target raise is allocated across three buckets: RMB 1.54 billion for BCI research and development, RMB 0.41 billion for manufacturing infrastructure, and RMB 0.55 billion for working capital. The Paper, citing the prospectus, reports that Neuracle’s 2025 revenue crossed RMB 100 million (approximately $14 million) for the first time, against a net loss of RMB 230 million (approximately $32 million). Pre-IPO valuation in the most recent private round was approximately RMB 4 billion (approximately $550 million at current rates).

Pre-IPO investors include Sequoia China, Co-win, China Merchants, and Baidu Ventures. Disclosed funding across angel through Series E rounds is approximately $103 million. The CITIC Securities IPO guidance (辅导) filing completed on 4 February 2026, four months before the SSE prospectus acceptance.

The two-horse race with BrainCo

BrainCo, the Hangzhou-based Chinese BCI maker that emerged out of Harvard Innovation Labs in 2015, filed a confidential prospectus on the Hong Kong Stock Exchange in January 2026, per Bloomberg reporting at the time. Confidential filings at HKEX are not publicly visible until the listing process advances. Whether BrainCo’s January filing or Neuracle’s June acceptance reaches a first trading day first depends on the relative cadence of each exchange’s review process. Chinese financial press, including 21st Century Business Herald, has framed the dynamic explicitly as 脑机第一股之争, the BCI number-one stock race.

MicroPort NeuroTech (HKEX: 02172) listed on the Hong Kong Stock Exchange on 15 July 2022. The company’s product portfolio runs across neurovascular intervention devices for stroke, with BCI work present but not the central product line. The pure-play BCI listing remains open. Whichever of Neuracle (SSE STAR Market) or BrainCo (HKEX) clears first becomes the world’s first publicly listed pure-play BCI company.

How this fits the Industrial Builder posture

Neuracle is a Tsinghua spinout backed by Sequoia China, Baidu Ventures, and China Merchants. The capital stack is private commercial, not state cluster. The company is not headquartered in the Tianjin BCI Industrial Cluster, is not a named beneficiary of Order 818’s parallel commercial pathway, and is not formally tied to a Chinese state-mission programme analogous to South Korea’s K-Moonshot. The IPO filing is the second-largest live commercial milestone in the Chinese BCI category, after the NMPA approval in March 2026, and it routes through private venture capital and STAR Market rather than through the Industrial Builder vehicles that have been the dominant analytical frame for Chinese BCI commercial scale-up.

Private VC-backed Tsinghua spinouts routing capital through Shanghai’s STAR Market sit closer in architecture to a Boston biotech listing on Nasdaq than to a state-owned enterprise. The Industrial Builder label captures the regulatory and reimbursement architecture (Order 818, guided pricing, NMPA acceleration). It does not specify the commercial vehicle through which scale-up actually happens.

Inside BCI’s Asia-Pacific synthesis piece, published 21 June 2026, named SSE STAR Market and HKEX listings as the first forward signal to watch in the Industrial Builder bloc. The Neuracle filing came through a different vehicle than the Tianjin cluster but lands on the same listing track on the same exchange. Both signals matter. The Tianjin cluster operationalises state-coordinated BCI industrial scale-up. The Neuracle filing operationalises private VC-backed BCI commercial scale-up. They are the two parallel commercial tracks operating inside the same jurisdiction.

What to watch

Three signals over the next two quarters. First, the number and substance of SSE inquiry rounds (问询) Neuracle receives from the STAR Market review committee. Chinese pre-IPO companies typically receive two to three rounds of inquiry letters before listing committee approval, with each round addressing specific accounting, governance, and product-claims items. The pace and depth of these inquiries will signal whether Neuracle is on a fast-track or a deliberate review cadence.

Second, whether BrainCo’s confidential HKEX filing progresses to a publicly disclosed prospectus before Neuracle reaches CSRC registration. The relative pacing of the two exchanges will determine which company wins the first-listing race.

Third, whether the NEO’s commercial revenue trajectory accelerates between now and a listing date. The 2025 RMB 100 million revenue figure is the floor. STAR Market Standard 5’s four-year profitability clock starts at listing date, which puts revenue acceleration on a tight schedule.

A Neuracle listing, if it clears, sets the first public valuation comparable for the BCI category globally. Every subsequent BCI fundraise will be priced against the SSE STAR Market multiples this listing produces, from BrainCo’s parallel HKEX process to Synchron’s next private round to Paradromics’s commercial path beyond Connect-One. The first listing in any new device category is the comparable. The category has not had one until now.

Sources

• Shanghai Stock Exchange Neuracle filing PDF, 11 June 2026
• 21st Century Business Herald — Boruikang sprinting for first BCI stock
• Sina Finance — Neuracle IPO accepted, RMB 2.5B raise
• The Paper — 2025 revenue and loss disclosure, Standard 5 listing path
• Huxiu — STAR Market IPO accepted
• Securities Times — Sequoia, Baidu Ventures and China Merchants backing
• National Business Daily — CITIC Securities IPO guidance filing
• Pandaily — Boruikang files for IPO as China’s first BCI public company
• Nature Biotechnology — China approves first commercial invasive BCI
• MIT Technology Review — China world-first brain chip
• Bloomberg — BrainCo files for confidential HKEX IPO
• TechNode — BrainCo Hong Kong IPO sources